Opus Genetics (NASDAQ:IRD) Announces Earnings Results, Misses Expectations By $0.93 EPS

Opus Genetics (NASDAQ:IRD) announced its earnings results on Monday. The company reported ($1.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.93), Zacks reports. The company had revenue of $3.40 million for the quarter, compared to the consensus estimate of $11.10 million. Opus Genetics had a negative return on equity of 63.65% and a negative net margin of 324.45%.

Opus Genetics Price Performance

Shares of Opus Genetics stock traded down $0.03 on Monday, hitting $0.99. 66,180 shares of the company’s stock traded hands, compared to its average volume of 218,766. The firm’s fifty day moving average price is $1.08. Opus Genetics has a one year low of $0.81 and a one year high of $1.56. The company has a market cap of $31.57 million, a P/E ratio of -0.90 and a beta of 0.28.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Opus Genetics in a research note on Wednesday, February 19th.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.